跳至主要内容
临床试验/NCT01114854
NCT01114854已完成1 期

A Conversion Study to Determine the Relative Bioavailability of TPM MR vs TPM IR in Subjects With Epilepsy

Supernus Pharmaceuticals, Inc.9 个研究点 分布在 1 个国家目标入组 69 人开始时间: 2010年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
69
试验地点
9
主要终点
relative bioavailability at steady-state of TPM MR and TPM IR, as determined by TPM levels in plasma

研究概览

简要总结

This multi-center, two-treatment study compares the pharmacokinetic profiles of Immediate Release (IR) and Modified Release (MR) formulations of Topiramate (TPM) in patients with epilepsy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

盲法说明

It was a open-label study

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult male or female patients with epilepsy on stable doses of topiramate.
  • Able to voluntarily provide written informed consent to participate in the study.
  • Use of an effective form of birth control if of child-bearing potential.

排除标准

  • Diagnosis of status epilepticus, non-epileptic seizures, or any progressive CNS disease.
  • Recent or recurrent suicidal thoughts or ideation.
  • Clinically significant medical condition that may affect the safety of the subject.
  • Females who are pregnant or lactating.

研究组 & 干预措施

Topiramate IR followed by Topiramate ER

Other

Dosing with IR followed by dosing with ER

干预措施: Topiramate ER (Drug)

Topiramate IR followed by Topiramate ER

Other

Dosing with IR followed by dosing with ER

干预措施: Topiramate IR (Drug)

结局指标

主要结局

relative bioavailability at steady-state of TPM MR and TPM IR, as determined by TPM levels in plasma

时间窗: 2 weeks

次要结局

  • relative bioavailability of TPM MR immediately following switch from TPM IR, as determined by TPM levels in plasma(2 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验